RET fusions observed in lung and colorectal cancers are sensitive to ponatinib

Genomic studies are revolutionizing clinical oncology, but bridging the lab and the bedside requires the ability to efficiently interrogate rare genetic lesions in unexpected pathological settings using preclinical models. Oncogenes can exhibit intrinsic drug resistance to targeted therapy in differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozgit, Joseph M., Chen, Tzu-Hsiu, Song, Youngchul, Wardwell, Scott, Wang, Frank, Cai, Jie, Li, Henry, Edgren, Henrik, Rivera, Victor M., Pritchard, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049858/
https://www.ncbi.nlm.nih.gov/pubmed/30038711
http://dx.doi.org/10.18632/oncotarget.25664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049858/
https://www.ncbi.nlm.nih.gov/pubmed/30038711
http://dx.doi.org/10.18632/oncotarget.25664

Ejemplares similares